Evaluation of Long-term efficacy, safety and predictors of Adalimumab in Crohn's disease: Japanese multicenter cohort study (ADJUST study)
Phase of Trial: Phase IV
Latest Information Update: 01 Nov 2017
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms ADJUST
- 01 Nov 2017 Status changed from active, no longer recruiting to completed, as per results presented at the 25th United European Gastroenterology Week.
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
- 29 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.